[Skip to Content]

Testing a drug that may be a treatment for Alzheimer's

Sharon Brangman, MD (photo by Jim Howe)

Sharon Brangman, MD (photo by Jim Howe)

Upstate Medical University is screening people who want to participate in a new, national clinical research study of a treatment for mild to moderate Alzheimer's disease. Called the T2 Protect AD, the study evaluates the drug troriluzole for its ability to protect against, slow down or even improve memory and thinking problems that increase as Alzheimer's progresses. Sharon Brangman, MD, a SUNY Distinguished Service Professor of Medicine and the chief of the Department of Geriatrics, tells about the study: -- Participants must be between the ages of 50 and 85 with a diagnosis of mild to moderate Alzheimer's. -- The study will last about a year and require nine medical visits. -- Each participant starts and ends with a magnetic resonance imaging (MRI) brain scan. Click here to learn more about the study or contact the Center of Excellence for Alzheimer's Disease at Upstate by calling 315-464-3285.

9-25-19-brangman.mp3 (24.97 MB) (Click to open in new window or Right-Click to save-as)
Top